| Dr Michael B Mcmurtry, DO | |
|
1025 S 2nd Ave, Walla Walla, WA 99362-4116 | |
| (509) 525-0480 | |
| (509) 527-8222 |
| Full Name | Dr Michael B Mcmurtry |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 22 Years |
| Location | 1025 S 2nd Ave, Walla Walla, Washington |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1750367579 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | OP60270915 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence St Mary Medical Center | Walla walla, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services - Washington | 2860552973 | 217 |
News Archive
The products of Unfors RaySafe (formerly Unfors Instruments), the international market leader in quality assurance for X-ray equipment, are known not only for their functionality and accuracy but also for their attractive design and intuitive operation. This has just been confirmed by a 24-strong panel of judges who have awarded one of this year's coveted red dot design awards to the Swedish company and to their design partner Lots for the RaySafe S1 software solution.
Purdue Pharma L.P. of Stamford, Connecticut and Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin (oxycodone HCl controlled-release) Tablets.
Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.
› Verified 3 days ago
| Entity Name | Providence Health & Services - Washington |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922259738 PECOS PAC ID: 2860552973 Enrollment ID: O20081223000478 |
News Archive
The products of Unfors RaySafe (formerly Unfors Instruments), the international market leader in quality assurance for X-ray equipment, are known not only for their functionality and accuracy but also for their attractive design and intuitive operation. This has just been confirmed by a 24-strong panel of judges who have awarded one of this year's coveted red dot design awards to the Swedish company and to their design partner Lots for the RaySafe S1 software solution.
Purdue Pharma L.P. of Stamford, Connecticut and Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin (oxycodone HCl controlled-release) Tablets.
Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael B Mcmurtry, DO Po Box 1398, Walla Walla, WA 99362-0309 Ph: (509) 525-0480 | Dr Michael B Mcmurtry, DO 1025 S 2nd Ave, Walla Walla, WA 99362-4116 Ph: (509) 525-0480 |
News Archive
The products of Unfors RaySafe (formerly Unfors Instruments), the international market leader in quality assurance for X-ray equipment, are known not only for their functionality and accuracy but also for their attractive design and intuitive operation. This has just been confirmed by a 24-strong panel of judges who have awarded one of this year's coveted red dot design awards to the Swedish company and to their design partner Lots for the RaySafe S1 software solution.
Purdue Pharma L.P. of Stamford, Connecticut and Teva Pharmaceuticals USA, Inc. of North Wales, Pennsylvania have agreed to end their lawsuit concerning certain Purdue Pharma patents on OxyContin (oxycodone HCl controlled-release) Tablets.
Colorectal cancer is a significant public health problem for which differing treatment regimes hold different benefits in associated efficacy, safety and tolerability, according to study findings showcased at the 13th European Cancer Conference (ECCO).
Inspire Pharmaceuticals, Inc. announced today that the results from its first Phase 3 clinical trial with denufosol tetrasodium for cystic fibrosis (CF), TIGER-1, have been published in the peer-reviewed publication, American Journal of Respiratory and Critical Care Medicine (AJRCCM). Denufosol is an investigational, inhaled, novel ion channel regulator currently in Phase 3 clinical development for the treatment of CF.
Administration of colchicine, a plant-based medication commonly used to treat gout, before and after cardiac surgery showed mixed results in reducing potential complications from this type of surgery, but it did increase the risk of gastrointestinal adverse effects, according to a study published by JAMA.
› Verified 3 days ago
Dr. Philip A Green, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Shirley Robin Vonhaven, DO Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 401 W Poplar, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5950 | |
Jared L Wutzke, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 | |
Dr. Morgan C Galante, DO Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 1111 S 2nd Ave, Walla Walla, WA 99362 Phone: 509-897-3700 | |
Joilo Barbosa, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 123 E Main St # 268, Walla Walla, WA 99362 Phone: 509-529-2966 | |
Aaron B Jones, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Emergency Department, Walla Walla, WA 99362 Phone: 509-525-3320 | |
Eric Trent Brown, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 W Poplar St, Psmmc Er, Walla Walla, WA 99362 Phone: 509-522-5802 Fax: 509-522-5541 |